CURRICULUM VITAE

Kirk E. Hevener, PharmD, PhD Assistant Professor, Department of Pharmaceutical Sciences

University of Tennessee, College of Pharmacy

DATE January 15, 2020

CONTACT INFORMATION University of Tennessee - College of Pharmacy

881 Madison Ave, Ste 671 Memphis, TN 38163 (901) 448-1474 office khevener@uthsc.edu or khevener@gmail.com

EDUCATION University of Tennessee, Memphis, TN

Ph.D. in Pharmaceutical Sciences Thesis: “Structure and Ligand-Based Design of Novel Antimicrobial Agents” Research Advisor: Dr. Richard E. Lee, Professor

Dec, 2008

University of Tennessee, Memphis, TN Pharm.D. (Honors)

May, 2005

Tennessee State University, Nashville, TN B.S. in Chemistry (Summa cum Laude) Areas of Concentration: Physical Chemistry, Organic Chemistry

Dec, 2005

POSTGRADUATE EDUCATION

Postdoctoral Training

University of Illinois, Chicago, IL Postdoctoral Research Fellow, Center for Pharmaceutical Biotechnology (Dr. Michael Johnson, Professor Emeritus)

2009 - 2013

St. Jude Children’s Research Hospital, Memphis, TN Postdoctoral Research Associate, Dept. of Structural Biology & Dept. of Chemical Biology & Therapeutics (Dr. Stephen White & Dr. Richard Lee)

2008 - 2009

Courses and Workshops Attended

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY Workshop on Leadership in Biosciences

Mar 22 – 25, 2019

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY Protein Purification and Characterization

Apr 6 – 19, 2011

2 Hevener, Kirk E. Curriculum Vitae

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY X-ray Methods in Structural Biology

Oct 17 – Nov 1, 2011

PROFESSIONAL LICENSURES

Pharmacist (Active), Tennessee 2005 - Present

MILITARY SERVICE

U.S. Navy, Petty Officer 3rd Class, Hospital Corps. Honorable Discharge • Naval Hospital, Camp Pendleton, CA • Naval School of Health Sciences, Portsmouth, VA • Naval Hospital, Beaufort, SC • Naval Training Center, Great Lakes, IL

1993 - 1997 1992 - 1993 1992 - 1992 1991 - 1992

EMPLOYMENT HISTORY

Academic Appointments University of Tennessee Health Science Center, College of Pharmacy

Member, Center of Excellence for Pediatric Experimental Therapeutics Sep 2018

University of Tennessee Health Science Center, College of Pharmacy Member, Drug Discovery Center

Aug 2017

University of Tennessee Health Science Center, College of Pharmacy Assistant Professor (Tenure Track) Department of Pharmaceutical Sciences

2017 - Present

Idaho State University, College of Pharmacy Assistant Professor (Tenure Track) Department of Biomedical and Pharmaceutical Sciences

2013 - 2017

Other Employment

USA Drugs, Memphis, TN Pharmacist, Community (Part-Time) Part-time pharmacy practice, community/retail setting.

2005 - 2009

University of Tennessee, Health Sciences Center, Memphis, TN Instructor (Part-Time), Drug Information Center Supervised professional pharmacy students on rotation in the College of Pharmacy’s Drug Information Center. Reviewed and approved drug information student responses.

2005 - 2008

PROFESSIONAL SOCIETY MEMBERSHIPS American Association for the Advancement of Science (Full, Active) 2016 - Present

Molecular Graphics and Modeling Society (Full Member, Active) 2008 - Present

Society of Infectious Disease Pharmacists (Full Member, Active) 2006 - Present

3 Hevener, Kirk E. Curriculum Vitae

American Society for Microbiology (Full Member, Active) 2004 - Present

American Chemical Society (Full Member, Active) 2002 - Present

ACS Technical Divisions: Chemical Biology, Medicinal Chemistry, Computational Chemistry

2002 - Present

American Association of Colleges of Pharmacy (Full Member, Active) 2002 - Present

Cheminformatics and QSAR Society (Inactive) 2008 - 2010

American Association of Pharmaceutical Scientists (Inactive) 2002 - 2008

HONORS AND AWARDS

Outstanding Alumnus, Phi Delta Chi – Omega Chapter, University of Tennessee, College of Pharmacy

May, 2019

Professor of the Year Award, Phi Delta Chi - Omega Chapter, University of Tennessee, College of Pharmacy

Mar, 2019

ITHS ‘Rising Star’ Award, University of Washington, Career Development Program

2015 - 2017

New Investigator Award, American Association of Colleges of Pharmacy

2013 - 2014

NRSA Fellow (T32 Postdoctoral Trainee), University of Illinois at Chicago, MOST Program

2011 - 2013

Best Poster Presentation; University of Illinois at Chicago, College of Dentistry Clinic & Research Day (Basic Sciences Category)

Mar, 2012

Kirk Hevener Scholarship, annually awarded by Omega Chapter of Phi Delta Chi, UTHSC, College of Pharmacy

2008

Robert A. Margarian Outstanding Podium Presentation Award, 34th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting

2007

Pre-Doctoral Fellowship, American Foundation for Pharmaceutical Education

2006 - 2008

Rho Chi Pharmacy Honor Society, Inductee 2005

Phi Lambda Sigma Pharmacy Leadership Society, Inductee 2004

ADMINISTRATIVE SERVICE

Institutional Service

Member, Computing and Technology Committee, University of Tennessee Health Science Center

2019 - Present

4 Hevener, Kirk E. Curriculum Vitae

Senator-at-Large, UTHSC Faculty Senate, University of Tennessee, College of Pharmacy

2019 - Present

Member, Pharmacy Faculty Organization, University of Tennessee, College of Pharmacy

2018 - Present

Adviser, Phi Delta Chi -Omega Chapter, University of Tennessee, College of Pharmacy

2017 - Present

Member, Student Learning Outcomes Ad Hoc Committee, University of Tennessee College of Pharmacy

Fall, 2017

Member, Graduate Council, Idaho State University 2015 - 2017

Member, Preceptor Advisory Council, Idaho State University 2015 - 2017

Chair, Graduate Education and Faculty Affairs Research Committee, Idaho State University, College of Pharmacy

2014 - 2017

Member, Institutional Biosafety Committee, Idaho State University 2013 - 2017

Graduate Program Coordinator, Idaho State University, College of Pharmacy, Department of Biomedical and Pharmaceutical Sciences

2014 - 2016

Member, Assessment Committee, Idaho State University, College of Pharmacy

2013 - 2014

President, Student Government Association Executive Committee, University of Tennessee Health Science Center

2005 - 2006

Member, Board of Governors, UT National Alumni Association 2005 - 2006

Professional Service

Member, DoD PRMRP Study Section, DIS-AMR-1 – Peer Reviewed Medical Research Program – Discovery Award

May, 2019

Member, NIH Study Section, ZAI1 GEB-I (C1) – Vaccine Adjuvant Discovery Program

November, 2018

Member, NIH Study Section, ZRG1 IDM S 81 – Infectious Disease and Microbiology AREA Review

November 3, 2017

Member, Editorial Advisory Board, Contagion® Live 2016 - Present

Member, Chemistry Section Nominating Committee, American Association of Colleges of Pharmacy

2016 - 2017

Member, Research Committee, Society of Infectious Diseases Pharmacists

2015 - 2016

5 Hevener, Kirk E. Curriculum Vitae

Regional Director of Alumni Affairs, Phi Delta Chi Professional Pharmacy Fraternity, Mountain Region

2013 - 2016

Ad Hoc Reviewer: Biochimie (1), Mol Biol Reports (1), 2020

Ad Hoc Reviewer: J. Med. Chem. (2), Biochimie (1), Biochemistry (1), 2019

Ad Hoc Reviewer: BMC Bioinformatics (1), J. Med. Chem. (2), J. Chem. Inf. Model. (1), PLOS One (1)

2018

Ad Hoc Reviewer: PLOS One (1) 2017

Ad Hoc Reviewer: Journal of Molecular Graphics & Modeling (1), Journal of Medicinal Chemistry (2)

2016

Ad Hoc Reviewer: Journal of Chemical Information and Modeling (1), PLoS ONE (1), ChemMedChem (1), Bioorganic & Med. Chem. Letters (1)

2015

Ad Hoc Reviewer: Bioorganic and Medicinal Chemistry Letters (1), Journal of Medicinal Chemistry (3), PLoS ONE (2), ChemMedChem (1)

2014

Ad Hoc Reviewer: J. Comput.-Aided Mol. Design (1), J. Mol. Graphics and Model. (1), J. Enzyme Inhib. and Med. Chem. (1), Australian Journal of Chemistry (1), Current Pharmaceutical Design (1)

2013

Session Presider, Computational Study of Water, Comp Division, 242nd ACS National Meeting, Denver, CO, USA

Aug 28, 2011

Regional Director of Collegiate Affairs, Phi Delta Chi Professional Pharmacy Fraternity, Midwest Region

2010 - 2011

Regional Correspondent, Phi Delta Chi Professional Pharmacy Fraternity, South Central Region

2004 - 2005

TEACHING SERVICE

Courses Taught

Course Instructor, University of Tennessee, College of Pharmacy Cardiology I (PHCY 1200), PharmD Program (P1 Year) 6 contact hours/semester, ~190 pharmacy students (Annual)

Spring, 2018 - 2020

Course Instructor, University of Tennessee, College of Pharmacy Infectious Diseases (PHCY 2210), PharmD Program (P2 Year) 9 contact hours, ~190 pharmacy students

Spring, 2020

Course Instructor, University of Tennessee, College of Pharmacy Surgery, Crit. Care, Transplant (PHCY 2202), PharmD Program (P2 Year) 2 contact hours, ~190 pharmacy students (Annual)

Spring, 2019 - 2020

6 Hevener, Kirk E. Curriculum Vitae

Course Instructor, University of Tennessee, College of Pharmacy Organic Medicinal Chemistry I (MEDC 810), Graduate Program, 12 contact hours/semester, 4-8 graduate students (Annual)

Fall, 2017 - 2019

Course Instructor, University of Tennessee, College of Pharmacy Endocrinology (PHCY 2100), PharmD Program (P2 Year) 4 contact hours/semester, ~200 pharmacy students (Annual)

Fall, 2018 - 2019

Course Instructor, University of Tennessee, College of Pharmacy Pulmonology (PHCY 2102), PharmD Program (P2 Year) 3 contact hours/semester, ~200 pharmacy students (Annual)

Fall, 2018 - 2019

Facilitator, University of Tennessee, College of Pharmacy Foundations of Pharmacy (PHCY 1104), PharmD Program, 16 contact hours/semester, 10 PharmD students (Annual)

Fall, 2017 - 2019

Course Instructor, University of Tennessee, College of Pharmacy Infectious Diseases II (PHCY 2201), PharmD Program (P2 Year) 6 contact hours, ~190 pharmacy students

Spring, 2019

Course Director, University of Tennessee, College of Pharmacy Infectious Diseases I (PHCY 2200), PharmD Program (P2 Year) Supervise 42 contact hours/semester, ~180 pharmacy students

Spring, 2019

Course Director, University of Tennessee, College of Pharmacy Computer-Aided Molecular Design II (MEDC 822), Graduate Program 3 contact hours/week, 4 graduate students/1 postdoc

Fall, 2018

Facilitator, University of Tennessee College of Pharmacy Medicinal Chemistry Journal Club (MEDC 819), Graduate Program 12 contact hours/semester, 7 graduate students

Spring, 2018

Course Director, University of Tennessee, College of Pharmacy Computer-Aided Molecular Design I (MEDC 821), Graduate Program 3 contact hours/week, 8 graduate students

Fall, 2017

Course Director, Idaho State University, College of Pharmacy PhysicoChemical Basis of Drug Action (PHAR 9924), PharmD Program 3 contact hours/week, 84 pharmacy students

Fall, 2016

Course Director, Idaho State University, College of Pharmacy Critical Literature Evaluation (PSCI 6603), Grad. Program in Pharm. Sci., 1 contact hours/week, 5 graduate students (Annual)

Fall, 2015 - 2016

Course Director, Idaho State University, College of Pharmacy Respons. Conduct in Research (PSCI 5508), Grad. Program in Pharm. Sci., 1 contact hours/week, 3 - 4 graduate students (Annual)

Spring, 2015 - 2016

7 Hevener, Kirk E. Curriculum Vitae

Course Director, Idaho State University, College of Pharmacy Cheminformatics & QSAR (PSCI 6671), Graduate Program in Pharm. Sci., 3 contact hours/week, 2 graduate students

Spring, 2015

Course Instructor, Idaho State University, College of Pharmacy Pharmacotherapy VI Infectious Diseases (PHAR 9967), PharmD Program, 12 contact hours/semester, 72 - 80 pharmacy students (Annual)

Fall, 2014 - 2016

Course Director, Idaho State University, College of Pharmacy Drug Discovery (PSCI 6620), Graduate Program in Pharm. Sci., 3 contact hours/week, 2 graduate students (Biennial)

Spring, 2014 - 2016

Course Director, Idaho State University, College of Pharmacy Graduate Seminar (PSCI 6601), Graduate Program in Pharm. Sci., 1 contact hours/week, 3 graduate students (Biennial)

Spring, 2014 - 2016

Course Director, Idaho State University, College of Pharmacy Scientific Communication (PSCI 6603), Graduate Program in Pharm. Sci., 3 contact hours/week, 1 to 4 graduate students (Annual)

Fall, 2013-2015

Invited Lecturer, University of Illinois at Chicago, College of Pharmacy Drug Design (MDCH-572), Graduate Program in Medicinal Chemistry 10, 1st & 2nd year graduate students, 5 hours (ligand-based drug design)

Spring, 2012

Graduate Students Trained

Ms. Lamya Alghanim (Ph.D., Adviser) University of Tennessee, College of Pharmacy

2019 - Present

Miss Kristiana Watson (Pharm.D./Ph.D., Adviser) University of Tennessee, College of Pharmacy

2018 - Present

Dr. Jesse Jones, Pharm.D. (Ph.D., Adviser) University of Tennessee, College of Pharmacy

2013 - 2019

Ms. Farjana Afrin (Ph.D., Adviser) Idaho State University, College of Pharmacy

2016 - 2017

Mr. Dipesh Budhathoki (M.S., Adviser) Idaho State University, College of Pharmacy

2015 - 2017

Thesis/Dissertation Committees

Mr. Parker Reitler, Adviser: Dr. Glen Palmer (UTHSC) University of Tennessee, College of Pharmacy

2018 - Present

Mr. Charlie Wright, Adviser: Dr. Taosheng Chen (SJCRH) University of Tennessee, College of Medicine

2018 - Present

8 Hevener, Kirk E. Curriculum Vitae

Ms. Nicole Vita, Adviser: Dr. Richard Lee (SJCRH) University of Tennessee, College of Pharmacy

2017 - Present

Mr. Christian DeJarnette, Adviser: Dr. Glen Palmer (UTHSC) University of Tennessee, College of Pharmacy

2017 - Present

Mr. Todd Perkins, Adviser: Dr. Amy Bryant (Boise VAMC) Idaho State University, College of Pharmacy

2015 - 2016

Dr. Nicole Frank (Ph.D.), Adviser: Dr. Todd Talley Idaho State University, College of Pharmacy

2013 - 2016

RESEARCH SUPPORT

Active Support

Development and Evaluation of Inhibitors of the C. difficile Enzyme, FabK, as Microbiome-Sparing Antibacterials DoD CDPRMRP Investigator-Initiated Research, PR191438, Role: PI Total Direct Costs: $1,200,000

1/2020 – 12/2022 (Award Notice)

Completed Support

Investigation of FAS-II enzyme, FabK, as a druggable target for C. diff. NIH/NIAID 1R21AI126755, Role: Co-PI Total Direct Costs: $275,000

6/25/16 – 11/30/19

Halogen Bond Contributions to Protein-Ligand Binding Free Energy NSF XSEDE Resource Allocation, MCB170030. Role: PI Total Awarded SU’s: 100,000 (estimated value $3,908)

2/21/17 – 2/20/18

Drug Repurposing Screening against C. difficile Enoyl-ACP Reductase ITHS Rising Stars Program (Univ. Washington, CTSA), Role: PI (subaward) Direct Costs: $15,000

6/1/15 – 5/31/17

FabK, Enoyl-ACP Reductase II, a novel and selective target for C. difficile Idaho State University, Faculty Seed Grant, Role: PI Direct Costs: $20,000 (Total)

5/16/16 – 2/17/17

Topoisomerase I, a novel target for streptococcal-associated infection Idaho State University, Faculty Seed Grant, Role: PI Direct Costs: $20,000 (Total)

5/16/14 – 8/15/15

A Novel Assay for Drug Repurposing against Bacterial Topoisomerase I NIH 1U54GM104944 (UNLV, IDEA-CTR), Role: PI (subaward) Direct Costs: $10,000

12/10/14 – 6/30/15

Enoyl Reductase II (FabK), a selective antibacterial target for C. difficile AACP New Investigator Award, Role: PI Direct Costs: $10,000 (Total)

1/1/14 - 12/31/14

9 Hevener, Kirk E. Curriculum Vitae

Discovery of Novel Therapeutics Targeting Bacterial Fatty Acid Synthesis XSEDE Resource Allocation (53,000 SU’s), TG-MCB130123. Role: PI

4/24/13 - 4/24/14

Multidisciplinary Oral Science Training Program NIH 5T32DE018381. Role: Trainee, 100% (Dipietro, Luisa A, PI) Direct Costs (Stipend & Training): $109,372 (total)

1/11/11 - 1/13/13

Recent Applications Scored, Not Funded

Discovery of inhibitors of the FAS-II enzyme, FabK, as narrow-spectrum C. difficile antibacterials NIH/NIAID 1-R01-AI143736-01A1, Role: PI, Total Costs: $3,384,540

7/5/19 (submitted) Status: (35th %)

PATENTS, INVENTIONS, AND COPYRIGHTS

Copyright, TXu001593682, Kirk Edward Hevener. Structure- and Ligand-Based Design of Novel Antimicrobial Agents.

Nov 2, 2008

Int. Patent. Appl. PCT/US2013/059280. Johnson, M.E.; Ghosh, A.K.; Mehboob, S.; Hevener, K.E. (Assignee: University of Illinois at Chicago) Enoyl Reductase (FabI) Inhibitors with Antibacterial Activity

Sep. 11, 2013

PUBLICATIONS

Peer-Reviewed Journal Articles

Citations Indices Citations: 956 h-index: 15 i10-index: 17

1. The Second-Generation Anti-Diabetic Sulfonylureas Inhibit Candida albicans and Candidalysin Mediated Activation of the NLRP3 Inflammasome. Lowes DJ, Hevener KE, Peters BM. Antimicrob Agents Chemother. 2019, (Online ahead of print).

2. Constitutive Expression of the Cryptic vanGCd Operon Promotes Vancomycin Resistance in Clostridioides Difficile Clinical Isolates. Shen W-J, Deshpande A, Hevener KE, Endres BT, Garey KW, Palmer KL, Hurdle JG. J Antimicrob Chemother. 2019, (Online ahead of print).

3. Small-molecule inhibition of the Clostidioides difficile FAS-II enzyme, FabK, results in selective activity. Jones JA, Prior A, Mareddy RKR, Wahrmund R, Hurdle JG, Sun D, Hevener KE. ACS Chem Biol. 2019, 14(7), 1528-1535.

4. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA topoisomerase I from the Gram-positive model organism Streptococcus mutans. Jones JA, Hevener KE. Biochem Biophys Res Commun. 2019, 516(2), 333-338.

5. Identification of small molecules exhibiting oxacillin synergy through a novel assay for inhibition of vraTSR expression in methicillin-resistant Staphylococcus aureus. Lee H, Boyle-Vavra S, Ren J, Jarusiewicz J, Sharma LK, Hoagland DT, Yin S, Zhu T, Hevener KE, Ojeda I, Daum RS, Johnson ME. Antimicrob Agents Chemother. 2019, 63(9), e02593-18.

Altmetric Color Legend

10 Hevener, Kirk E. Curriculum Vitae

6. The Vacuolar Ca2+ ATPase Pump Pmc1p is Required for Candida albicans Pathogenesis. Luna-Tapia A, DeJarnette C, Sansevere E, Reitler P, Butts A, Hevener KE, Palmer GE. mSphere. 2019, 4(1), e00715-18.

7. The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection. Marreddy RKR, Wu X, Sapkota, M, Prior AM, Jones JA, Sun D, Hevener KE, Hurdle JG. ACS Infect. Dis. 2019, 5(2), 208-217.

8. Pharmacophore Modeling, Synthesis, and Antibacterial Evaluation of Chalcone and Derivatives. Zhang M, Prior A, Maddox M, Shen WJ, Hevener KE, Bruhn D, Lee REB, Singh A, Reinicke J, Simm ons C, Hurdle JG, Lee RE, Sun D. ACS Omega. 2018, 3 (12), 18343-60.

9. Recent developments in topoisomerase targeted cancer chemotherapy. Hevener KE*, Verstak TA, Lutat KE, Riggsbee DL, Mooney, JW. Acta Pharm. Sin. B. 2018, 8 (6), 844-861.

10. Structural Characterization of Porphyromonas gingivalis Enoyl-ACP Reductase II (FabK). Hevener KE*, Santarsiero BD, Lee H, Jones JA, Boci T, Johnson ME, Mehboob S*. Acta Crystallogr F Struct Biol Commun. 2018, 74, 105-112.

11. Recent Advances in the Rational Design and Optimization of Antibacterial Agents. Jones JA, Virga KG, Gumina G, Hevener KE*. MedChemComm. 2016, 7 (9), 1694-1715. MedChemComm ‘Hot Article’

12. Rifamycin Resistance in Clostridium difficile is Generally Associated with a Low Fitness. Dang U, Zamora I, Hevener KE, Adhikari S, Wu X, Hurdle JG. Antimicrob Agents Chemother. 2016, 60 (9), 5604-5607.

13. A simplified protocol for high-yield expression and purification of bacterial topoisomerase I. Jones JA, Price E, Miller D, Hevener KE*. Protein Expr Purif. 2016, 124, 32-40.

14. Comparison of radii sets, entropy, QM methods, and sampling on MM-PBSA, MM-GBSA, and QM/MM-GBSA ligand binding energies of F. tularensis enoyl-ACP reductase (FabI). Su PC, Tsai CC, Mehboob S, Hevener KE*, Johnson ME*. J Comp Chem. 2015, 36 (25), 1859-1873.

15. Structural and Biological Evaluation of a Novel Series of Benzimidazole Inhibitors of Francisella tularensis Enoyl-ACP Reductase (FabI). Mehboob S, Song J, Hevener KE, Su PC, Boci T, Brubaker L, Truong L, Deng J, Cook JL, Santarsiero BD, Ghosh AK, Johnson ME. Bioorg Med Chem Lett. 2015, 25 (6), 1292-1296.

16. High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple Hepatitis C Virus genotypes. Lee H, Zhu T, Patel K, Zhang YY, Truong L, Hevener KE, Subramanya G, Gatuz JL, Sarkar A, Jeong HY, Uprichard SL, and Johnson ME. PLoS One. 2013, 8 (10), e75144.

17. Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based Upon a Critical Literature Analysis. Zhu T, Cao C, Su P-C, Patel R, Shah D, Chokshi HB, Szukala R, Johnson ME, Hevener KE*. J Med Chem. 2013, 56 (17), 6560-6572.

18. Synergistic Inhibitor Binding to the Papain-Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications. Lee H, Cao S, Hevener KE, Truong L, Gatuz JL, Patel K, Ghosh AK, and Johnson ME. ChemMedChem. 2013, 8 (8), 1361-1372.

11 Hevener, Kirk E. Curriculum Vitae

19. Fragment-based lead discovery using a multi-domain, parallel MM/PBSA simulation screening protocol. Zhu T, Lee H, Lei H, Jones C, Patel K, Johnson ME, Hevener KE*. J Chem Inf Model. 2013, 53 (3), 560-572.

20. High-level expression, purification, and characterization of Staphylococcus aureus dihydrootase (PyrC) as a cleavable His-SUMO fusion. Truong L, Hevener KE, Rice AJ, Patel K, Johnson ME, Lee H. Protein Expr Purif. 2013, 88 (1), 98-106.

21. Expression, purification and characterization of the enoyl-ACP reductase II (FabK) from Porphyromonas gingivalis. Hevener KE*, Mehboob S, Boci T, Truong K, Santarsiero BD, Johnson ME. Protein Expr Purif. 2012, 85 (1), 100-108.

22. Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors. Mehboob S, Hevener KE, Truong K, Boci T, Santarsiero BD, Johnson ME. J Med Chem. 2012, 55 (12), 5933-41.

23. Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. Hevener KE, Mehboob S, Su PC, Truong K, Boci T, Deng J, Ghassemi M, Cook JL, Johnson ME. J Med Chem. 2012, 55 (1), 268-79.

24. Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase. Hevener KE, Yun MK, Qi J, Kerr ID, Babaoglu K, Hurdle JG, Balakrishna K, White SW, Lee RE. J Med Chem. 2010, 53 (1), 166-77.

25. A Statistical Framework to Evaluate Virtual Screening. Zhao W, Hevener KE, White SW, Lee RE, Boyett JM. BMC Bioinformatics. 2009, 10, 225.

26. Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW, Lee RE. J Chem Inf Model. 2009, 49 (2), 444-60.

27. Quantitative Structure-Activity Relationship Studies on Nitrofuranyl Antitubercular Agents. Hevener KE, Ball DM, Buolamwini JK, Lee RE. Bioorg Med Chem. 2008, 16 (17), 8042-53.

28. Structure-activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors. Virga KG, Zhang YM, Leonardi R, Ivey RA, Hevener K, Park HW, Jackowskie S, Rock CO, Lee RE. Bioorg Med Chem. 2006, 14, 1007-20.

29. Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. Tangallapally RP, Yendapally R, Lee RE, Hevener K, Jones VC, Lenaerts AJ, McNeil MR, Wang Y, Franzblau S, Lee RE. J Med Chem. 2004, 47 (21), 5276-83.

30. The structure of the pantothenate kinase.ADP.pantothenate ternary complex reveals the relationship between the binding sites for substrate, allosteric regulator, and antimetabolites. Ivey RA, Zhang YM, Virga KG, Hevener K, Lee RE, Rock CO, Jackowski S, Park HW. J Biol Chem. 2004, 279 (34), 35622-9.

12 Hevener, Kirk E. Curriculum Vitae

Non-Peer-Reviewed Journal Articles

1. Nasritdinova, U. & Hevener, K.E. Vaginal Microbiome Transplantation Effective in Intractable Bacterial Vaginosis. Contagion Live. 2019 Dec 9. https://www.contagionlive.com/news/vaginal-microbiome-transplantation-effective-in-intractable-bacterial-vaginosis

2. Hevener, K.E. Study Shows Sulfonamide Antibacterials Capable of Reversing Azole Resistance in Candida albicans. Contagion Live. 2018 Jun 28. http://www.contagionlive.com/publications/contagion/2018/june/study-shows-sulfonamide-antibacterials-capable-of-reversing-azole-resistance-in-candida-albicans

3. Avad, K.A. & Hevener, K.E. Pharmacomicrobiomic Study Shows Significant Gut Bacteria Role in Drug Metabolism and Exposure. Contagion Live. 2019 Aug 20. https://www.contagionlive.com/news/pharmacomicrobiomic-study-shows-significant-gut-bacteria-role-in-drug-metabolism-and-exposure

Book Chapters

1. Hevener, K.E.; Ren, J.H.; Pesavento, R.; Ratia, K.; Lee, H.; Johnson, M.E. Hit-to-Lead: Hit Validation, Assessment, and Improvement of Drug-Like Properties. In Modern Advances in Drug Discovery, Lesburg, C., Ed. Elsevier: New York, NY, 2018; Vol. 610, p. 265-309.

2. Hevener, K.E. Medicinal Chemistry. In The APhA Complete Review for the FPGEE, 2nd ed., Boucher, B., Ed. American Pharmacist’s Association: Washington, DC, 2018. p. 87-110.

3. Hevener, K. E. Computational Toxicology Methods in Chemical Library Design and High-Throughput Screening Hit Validation. In Computational Toxicology, Nicolotti, O., Ed. Springer: New York, NY, 2018; Vol. 1800, p. 275-285.

4. Hevener, K. E.; Cao, S.; Zhu, T.; Su, P. C.; Mehboob, S.; Johnson, M. E. Special Challenges to the Rational Design of Antibacterial Agents. In Annual Reports in Medicinal Chemistry, Desai, M. C., Ed. Elsevier: Boston, MA, 2013; Vol. 48, p. 283-298.

Published Abstracts/Proceedings

1. Price, E.; Hurdle, J.; Sun, D.; Hevener, K. E. Enoyl Reductase II (FabK), a Selective Antibacterial Target for C. difficile. In Am J Pharm Ed, 2015, 79(5), Article S4.

Published Multimedia

1. Hevener, K.E. & Henderson, T. Interviewing Skills for Community Pharmacy Positions. Pharmacy Leaders Podcast Series. 2019 Jan 1. https://pharmacy.libsyn.com/ep-191-pdc-brothers-talk-about-interviewing-for-community-positions

2. Hevener, K.E. Are Narrow-Spectrum Antibiotics More Effective Against C. difficile? Contagion Live. 2017 Jun 23. https://www.contagionlive.com/videos/are-narrow-spectrum-antibiotics-more-effective-against-c-difficile

3. Hevener, K.E. What are the Drawbacks of Current Front-Line Drugs to Treat C. difficile Infection? Contagion Live. 2017 Jun 9. https://www.contagionlive.com/videos/what-are-the-drawbacks-of-current-frontline-drugs-to-treat-c-difficile-infection

13 Hevener, Kirk E. Curriculum Vitae

4. Hevener, K.E. Researching a Selective Antibacterial Effect Against Streptococcus mutans. Contagion Live. 2016 Sep 15. https://www.contagionlive.com/videos/researching-a-selective-antibacterial-effect-against-streptococcus-mutans

5. Hevener, K.E. Why Should We Start Using Narrow Spectrum Antibiotics? Contagion Live. 2016 Sep 12. https://www.contagionlive.com/videos/why-should-we-start-using-narrow-spectrum-antibiotics

6. Hevener, K.E. Identifying Pathogens for Targeted Therapy. Contagion Live. 2016 Sep 10. https://www.contagionlive.com/videos/identifying-pathogens-for-targeted-therapy

7. Hevener, K.E. How Does Topoisomerase I Differ from a Quinolone Antibacterial? Contagion Live. 2016 Sep 06. https://www.contagionlive.com/videos/how-does-topoisomerase-i-differ-from-a-quinolone-antibacterial

INVITED COMMUNICATIONS

1. Successfully transitioning from graduate studies to independence. Hevener, KE. Invited Keynote Address at University of Tennessee Health Science Center Graduate Research Day, Memphis, TN, April 20, 2018.

2. Enoyl-ACP reductase II (FabK), a narrow-spectrum druggable target for Clostridium difficile. Hevener, KH. Invited Seminar Presentation to Boise State University, Dept. of Biology, Boise, ID, September 24, 2015.

3. Recommendations for Hit Identification and Hit Optimization in Virtual Screening. Hevener, KE. Invited Symposium Presentation to 94th Annual Meeting of the AAAS Pacific Division, University of Nevada, Las Vegas, June 17, 2013.

4. Structural and Biochemical Characterization of Porphyromonas gingivalis Enoyl-ACP Reductase II (FabK), a Novel Antibacterial Target. Hevener, KE. Invited Symposium Presentation to 94th Annual Meeting of the AAAS Pacific Division, University of Nevada, Las Vegas, June 19, 2013.

5. Introduction to Academic Pharmacy Research Careers. Hevener, KE. Invited Presentation to the Academy of Student Pharmacists (APhA-ASP), University of Illinois at Chicago, College of Pharmacy, Chicago, IL, November 21, 2011.

6. Structure-Guided Virtual Screening against Dihydropteroate Synthase. Hevener, KE.; Ayers, K.; White, S.W. Invited Presentation to the Tennessee Structural Biology Symposium, Murfreesboro, TN, United States, June 21-23, 2007.

PROFFERED COMMUNICATIONS

Poster Presentations

1. Investigation of Narrow-Spectrum Targets in Antibacterial Drug Discovery. J.A. Jones, Y. Kong, D. Yang, J.G. Hurdle, R.K.R. Marreddy, and K.E. Hevener. ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal, Sept. 4-7, 2018.

14 Hevener, Kirk E. Curriculum Vitae

2. Targeting Bacterial Topoisomerase I. J.A. Jones, Y. Kong, D. Yang, K.E. Hevener. ASM Microbe, Atlanta, GA, United States, June 7-11, 2018.

3. Assay Development and Compound Screening Against Clostridium difficile Enoyl-Reductase II (FabK). J.A. Jones, A. Barba-Montoya, R.K.R. Mareddy, A.M. Prior, D. Sun, J.G. Hurdle, K.E. Hevener. ASM Microbe, Atlanta, GA, United States, June 9, 2018. (Presenter)

4. Targeting Bacterial Topoisomerase I as a Druggable and Selective Anti-Streptococcal Target. J.A. Jones, Y. Kong, D. Yang, and K.E. Hevener. New Antibacterial Discovery and Development, Gordon Research Conference, Ventura, CA, United States, March 11-16, 2018.

5. Assay Development and Compound Screening Against Clostridium difficile Enoyl-Reductase II (FabK). J.A. Jones, A. Barba-Montoya, R.K.R. Mareddy, A.M. Prior, D. Sun, J.G. Hurdle, K.E. Hevener. New Antibacterial Discovery and Development 2018 Gordon Research Conference, Ventura, CA, United States, March 11-16, 2018. (Presenter)

6. Targeting Type 1A Topoisomerases for Selective Anti-Streptococcal Drug Design. J.A. Jones, E. Price, K.E. Hevener. ASM Microbe Meeting, Boston, MA, United States, Sep 19, 2016.

7. Chemical and Genetic Validation of the Essentiality and Druggability of Fatty Acid Biosynthesis in Clostridium difficile. M. Sapkota, H. Lin, E. Price, M. Kumar, D. Sun, K. Hevener, J. G. Hurdle. ICAAC/ICC, San Diego, CA, United States, September 17-21, 2015.

8. Drug Repurposing Screening against the FabK Enzyme, a Novel Target in Clostridium difficile. Kirk Hevener, Emily Price, Julian Hurdle, Dianqing Sun. Mountain West Clinical Translational Research, Infrastructure Network (CTR-IN), Annual Meeting, Las Vegas, NV, United States, June 9-10, 2015. (Presenter)

9. Targeting Type 1A Topoisomerases for Selective Anti-Streptococcal Drug Design. J.A. Jones & K.E. Hevener. DNA Topoisomerases in Biology & Medicine Gordon Conference, Newry, ME, United States, Aug 10-15, 2014.

10. Hit Identification and Optimization in Virtual Screening. K.E. Hevener, T. Zhu, S. Cao, P. Su, M.E. Johnson. Computer-Aided Drug Discovery Gordon Conference, West Dover, VT, United States, July 22, 2013. (Presenter)

11. Development of High-Throughput Primary and Secondary Assays for P. gingivalis Enoyl Reductase II (FabK), a Novel Antibacterial Drug Target. K. E. Hevener, S. Mehboob, T. Boci, K. Truong, and M. E. Johnson. AAPS Annual Meeting & Exposition, Chicago, IL, United States, October 16, 2012. (Presenter)

12. Structural and Kinetic Studies of P. gingivalis Enoyl Reductase II (FabK), a Novel Target for Periodontal Infection. K. E. Hevener, S. Mehboob, T. Boci, K. Truong, B. D. Santarsiero, and M. E. Johnson. 32nd Midwest Enzyme Chemistry Conference, University of Illinois at Chicago, Chicago, IL, Unites States, October 13, 2012. (Presenter)

15 Hevener, Kirk E. Curriculum Vitae

13. Structural studies, SAR analyses, and antibacterial testing of a new class of F. tularensis enoyl reductase (FabI) inhibitors. S. Mehboob, J. Song, P. Su, K. Hevener, T. Boci, J. Deng, M. Ghassemi, Y. Zhang, B. Santarsiero, H. Jeong, J. L. Cook, A. K. Ghosh, M. E. Johnson. 52nd ICAAC, San Francisco, CA, Unites States, September 9 - 12, 2012.

14. Identification of novel F. tularensis enoyl reductase (FabI) inhibitors by shape matching, common pharmacophore, and dynamic pharmacophore modeling. Su, Pin-Chih; Hevener, K. E.; Mehboob, S.; Cao, S.; Lei, H.; Boci, T.; Truong, K.; Johnson, M. E. 243rd ACS National Meeting & Exposition, San Diego, CA, United States, March 25-March 29, 2012.

15. Characterization and Structural Evaluation of P. gingivalis FabK, a Novel Antibacterial Drug Target in the FAS-II Pathway. K. Hevener, S.a Mehboob, T. Boci, P.-C. Su, K. Truong, M. Johnson. University of Illinois at Chicago, College of Dentistry Clinic and Research Day, Chicago, IL, United States, March 8, 2012. (Presenter)

16. Discovery of a novel inhibitor scaffold against FabI from F. tularensis. Mehboob, Shahila; Hevener, Kirk E.; Truong, Kent; Johnson, Michael E. 242nd ACS National Meeting & Exposition, Denver, CO, United States, August 28-September 1, 2011.

17. Identification of Novel Inhibitors of F. tularensis FabI using Structure- and Ligand-based Virtual Screening. Hevener, K.; Mulhearn, D.; Mehboob, S.; Truong, K.; Truong, L.; Johnson, M. Computer-Aided Drug Design Keystone Conference, Whistler, BC, Canada, April 20-25, 2010. (Presenter)

18. Quantitative Structure-Activity Relationship Studies on Nitrofuranyl Antitubercular Agents. Hevener, K.; Ball, D.M.; Lee, R.E. 47th ICAAC, Chicago, IL, September 17-20, 2007. (Presenter)

19. Structure-Guided Virtual Screening against Dihydropteroate Synthase. Hevener, Kirk; Ball, David M.; Kerr, Iain; Yun, Mi-Kyun; Qi, Jianjun; White, Stephen W.; and Lee, Richard E. 234th ACS National Meeting, Boston, MA, United States, Aug. 19-23, 2007. (Presenter)

20. Structure-Guided Virtual Screening against DHPS Using Pharmacophore Filters and Fragment Constraints. Hevener, Kirk; Ball, David M.; Kerr, Iain; Yun, Mi-Kyun; Qi, Jianjun; White, Stephen W.; and Lee, Richard E. Computer-Aided Drug Design Gordon Research Conference, Tilton School, NH, United States, July 29 – August 3, 2007. (Presenter)

21. Molecular Docking Validation Based on Known DHPS Inhibitors. Hevener, K.; Ball, D.; Kerr, I., Babaoglu, K.; White, S. W.; Lee, R. E. Graduate Student Research Day, University of Tennessee HSC, Memphis, TN, United States, April 20th, 2007. (Presenter)

22. Structural and Mechanistic Studies of Sulfonamide Drug Resistance. Hevener, K.; Kerr, I.; Qi, J.; Virga, K.; Babaoglu, K.; Lee, R., White, S. W., Lee, R. E. 46th ICAAC, San Francisco, CA, United States, September 27-30, 2006. (Presenter)

23. Mechanistic Studies of Dihydropteroate Synthase. Lee, R.E.; Hevener, K.; Qi, J.; Kerr, I.; Babaoglu, K.; Mehra, S.; White, S.W. Bioorganic Chemistry Gordon Research Conference, Oxford, United Kingdom, Jul. 30-Aug. 4, 2006.

16 Hevener, Kirk E. Curriculum Vitae

24. Back to the future: A computational, chemical and structural study of dihydropteroate synthase as a target for the discovery of new antimicrobial agents. Lee, Richard E.; White, Stephen W.; Babaoglu, Kerim; Hevener, K.; Virga, K.; Qi, J.; Kerr, I.; Mehra, S. 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005.

25. Development of nitrofuranylamides as antituberculosis agents. Lee, R. E.; Tangallapally, R. P.; Yendapally, R.; Lee, R.E.B.; Daniels, A. J.; Hevener, K. 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005.

26. Structure-guided design of Pantothenate Kinase substrate analogues as potential inhibitors. Kris Virga, K. Hevener, Y.-M. Zhang, Charles Rock, Suzanne Jackowski, Hee Won Park, Robert Ivey, Richard Lee. 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004.

Podium Presentations

1. Enoyl-ACP reductase II, (FabK), a narrow-spectrum druggable target for Clostridium difficile. Kirk Hevener, Emily Price, Jesse Jones. Skaggs Biomedical Research Symposium, Pocatello, ID, United States, Aug 5, 2016.

2. Characterization and Advancement of Narrow-Spectrum Antibacterial Targets Capable of Minimizing Disruption to the Human Microbiome. Kirk Hevener, Jesse Jones, Shamsher Saini. Skaggs Biomedical Research Symposium, Missoula, MT, United States, Aug 14-15, 2014.

3. Targeting the FAS-II Pathway in P. gingivalis for Chronic Periodontitis. K.E. Hevener, S. Mehboob, T. Boci, K. Truong, B.D. Santarsiero, and M.E. Johnson. IADR/AADR/CADR General Session & Exposition, Seattle, WA, Unites States, Mar 20 – 23, 2013.

4. Discovery of a Novel and Potent Class of Bacterial Enoyl-Reductase (FabI) Inhibitors by Molecular Shape and Electrostatic Matching. Kirk Hevener, Shahila Mehboob, Pin-Chih Su, Kent Truong, Michael Johnson. 242nd ACS National Meeting, Denver, CO, United States, Aug 28 - Sep 1, 2011.

5. Structure-Guided Virtual Screening against Dihydropteroate Synthase Utilizing Pharmacophore Filters and Fragment-Based Constraints. Hevener, Kirk; Kerr, Iain; Yun, Mi-Kyun; Qi, Jianjun; White, Stephen W.; Lee, Richard E. 34th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Monroe, LA, United States, May 20-22, 2007.